Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03746067 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Pharmacokinetics of Single Doses of TS-134 in Healthy Volunteers
A Phase 1 study, sponsored by Taisho Pharmaceutical R&D.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT03746067: Completed Phase 1 study, sponsored by Taisho Pharmaceutical R&D.
NCT03746067 is a Phase 1 study that has completed, run by Taisho Pharmaceutical R&D. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03746067, a Phase 1 study, has completed, sponsored by Taisho Pharmaceutical R&D.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a Phase 1a study involving single oral dose of TS-134 in healthy male and female subjects. The safety, tolerability and pharmacokinetics of single dose of TS-134 will be evaluated.
Interventions
- DRUG Placebo
- DRUG TS-134
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2015-08-21 |
| Est. Completion | 2016-01-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03746067
The ClinicalTrials.gov registry entry for NCT03746067 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taisho Pharmaceutical R&D, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03746067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03746067 about?
NCT03746067 is a clinical study titled "Safety, Tolerability and Pharmacokinetics of Single Doses of TS-134 in Healthy Volunteers". This is a Phase 1a study involving single oral dose of TS-134 in healthy male and female subjects. The safety, tolerability and pharmacokinetics of single dose of TS-134 will be evaluated.
What is the current status of trial NCT03746067?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2015-08-21. Estimated completion is 2016-01-13.
What interventions are being tested in trial NCT03746067?
The interventions under investigation include: Placebo (DRUG), TS-134 (DRUG).
Who is sponsoring clinical trial NCT03746067?
This trial is sponsored by Taisho Pharmaceutical R&D, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.